June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
ERG/EOG Study in AMD Patients Treated with Ranibizumab (RAPTR)
Author Affiliations & Notes
  • Abdhish R Bhavsar
    Retina Center, Minnesota, Medina, Minnesota, United States
  • Footnotes
    Commercial Relationships   Abdhish Bhavsar, Genentech (F)
  • Footnotes
    Support  Genentech IST FVF4154s
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 3212. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Abdhish R Bhavsar; ERG/EOG Study in AMD Patients Treated with Ranibizumab (RAPTR). Invest. Ophthalmol. Vis. Sci. 2017;58(8):3212.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : The objective of this study is too determine the quantitative changes in the electrophysiologic amplitudes and latencies from baseline to month 12 in ranibizumab-treated eyes with exudative AMD (age related macular degeneration).

Methods : This is an open label study assessing ERG (electroretinogram) and EOG (electrooculogram) outcomes in patients with exudative AMD. ERG and EOG testing were conducted at baseline, and at 6 and 12 months after initiating ranibizumab treatment. Ten patients with exudative AMD were enrolled and received monthly intravitrous ranibizumab injections.

Results : No statistically significant differences were identified in ERG or EOG testing including: single photopic flash, maximal photopic response, rod response, 30 Hz flicker, notation of oscillatory potentials, multifocal ERG, EOG testing.

Conclusions : Monthly intravitreous injection of ranibizumab for treatment of exudative AMD did not demonstrate statistically significant ERG or EOG changes over the course of 1 year treatment.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.